Lisaftoclax

Lisaftoclax is an investigational new drug being developed by Ascentage Pharma for the treatment of hematological malignancies, particularly chronic lymphocytic leukemia and small lymphocytic lymphoma. It is a selective inhibitor of the B-cell lymphoma 2 protein, designed to restore the normal process of programmed cell death in cancer cells. As of 2024, lisaftoclax is undergoing multiple Phase 3 clinical trials, including studies in combination with BTK inhibitors for relapsed/refractory CLL/SLL.
In July 2025, lisaftoclax was approved in China for the treatment of CLL or SLL in adult patients who had received at least one prior systemic therapy.